CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation

AUTOR(ES)

Dai, F., Zhang, F., Sun, D., Zhang, Z.H., Dong, S.W., Xu, J.Z.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

19/05/2015

RESUMO

Allogeneic mesenchymal stem cells (allo-MSCs) have recently garnered increasing interest for their broad clinical therapy applications. Despite this, many studies have shown that allo-MSCs are associated with a high rate of graft rejection unless immunosuppressive therapy is administered to control allo-immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a co-inhibitory molecule expressed on T cells that mediates the inhibition of T-cell function. Here, we investigated the osteogenic differentiation potency of allo-MSCs in an activated immune system that mimics the in vivo allo-MSC grafting microenvironment and explored the immunomodulatory role of the helper T cell receptorCTLA4 in this process. We found that MSC osteogenic differentiation was inhibited in the presence of the activated immune response and that overexpression of CTLA4 in allo-MSCs suppressed the immune response and promoted osteogenic differentiation. Our results support the application of CTLA4-overexpressing allo-MSCs in bone tissue engineering.

Documentos Relacionados

• HOX gene analysis in the osteogenic differentiation of human mesenchymal stem cells
• Antiviral immune responses in CTLA4 transgenic mice.
• Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells
• CTLA4 mediates antigen-specific apoptosis of human T cells.
• Dinucleotide repeat polymorphism at the human CTLA4 gene